A novel chlorhexidine-releasing composite bone cement: Characterization of antimicrobial effectiveness and cement strength
Source abstract
Abstract
The addition of calcium phosphate fillers or antimicrobials to bone cements seems to produce inferior materials. In this study, a two-solution bone cement composite was designed for high viscosity and high pseudoplasticity to improve injection and mitigate the risk of extravasation. By pre-mixing these cements, the fillers are incorporated into the matrix and should not detrimentally affect the performance properties. To expand the functionality of this cement system, the addition of bioactive and antimicrobial phases were explored. Brushite and chlorhexidine were used as calcium phosphate filler and the antimicrobial phase, respectively. By controlling the free radical quenching mechanism provided by the chlorhexidine molecule, it was possible to achieve high polymer conversion rates. This phenomenon led to cement strength retention while successfully preventing microbial proliferation in an environment exposed to the cement surface. Based on these results, two-solution cement composite prepared with high concentrations of brushite and chlorhexidine diacetate salt hydrate may provide an attractive bioactive and antimicrobial cement for load-bearing applications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Dental materials and restorations · Endodontics and Root Canal Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bioengineering, University of Texas at Dallas, Richardson, TX, USA
Department of Molecular and Cell Biology, University of Texas at Dallas, Richardson, TX, USA
Department of Conservative Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
References (33)
Show source-provided references
1. 10.3390/ma709677910.3390/ma7096779 ↗
2. 10.1016/S0142-9612(03)00554-410.1016/S0142-9612(03)00554-4 ↗
3. 10.1016/j.nano.2010.10.00510.1016/j.nano.2010.10.005 ↗
4. 10.1177/03000605760040050310.1177/030006057600400503 ↗
5. Josefsson G · Clin Othop · 1981 · 159 · 194
6. 10.1016/S0883-5403(99)90061-X10.1016/S0883-5403(99)90061-X ↗
7. 10.1002/jbm.82010061010.1002/jbm.820100610 ↗
8. 10.1086/51462010.1086/514620 ↗
9. 10.2106/00004623-198668080-0002610.2106/00004623-198668080-00026 ↗
10. 10.3109/1745367860901475910.3109/17453678609014759 ↗
11. 10.1302/0301-620X.80B4.855510.1302/0301-620X.80B4.8555 ↗
12. 10.1038/733010.1038/7330 ↗
13. 10.1002/jbm.a.3003310.1002/jbm.a.30033 ↗
14. 10.1016/j.joen.2005.08.00610.1016/j.joen.2005.08.006 ↗
15. 10.1016/j.joen.2007.04.00610.1016/j.joen.2007.04.006 ↗
16. 10.1097/00004770-200406000-0001310.1097/00004770-200406000-00013 ↗
17. 10.1002/(SICI)1097-4636(199910)47:1<36::AID-JBM5>3.0.CO;2-R10.1002/(SICI)1097-4636(199910)47:1<36::AID-JBM5>3.0.CO;2-R ↗
18. Gilbert JL · J Biomed Mater Res B Appl Biomater · 2009 · 91 · 248
19. 10.1177/088391151243802710.1177/0883911512438027 ↗
20. ASTM F451-08 · 2008
21. 10.1038/7956810.1038/79568 ↗
22. 10.1128/AAC.48.11.4084-4088.200410.1128/AAC.48.11.4084-4088.2004 ↗
23. 10.1128/AAC.33.9.158810.1128/AAC.33.9.1588 ↗
24. 10.1086/66877010.1086/668770 ↗
25. 10.1128/CMR.12.1.14710.1128/CMR.12.1.147 ↗
26. Davies GE · Brit J Pharmacol · 1954 · 9 · 192
27. Botelho M · SADJ · 2004 · 59 · 51
28. 10.1016/j.joen.2007.08.00810.1016/j.joen.2007.08.008 ↗
29. 10.1016/0021-9290(90)90003-L10.1016/0021-9290(90)90003-L ↗
30. 10.1053/jhin.2002.135310.1053/jhin.2002.1353 ↗
31. 10.1016/j.cossms.2003.09.01210.1016/j.cossms.2003.09.012 ↗
32. 10.1016/j.actbio.2011.08.00510.1016/j.actbio.2011.08.005 ↗
33. 10.1016/S0142-9612(03)00293-X10.1016/S0142-9612(03)00293-X ↗